jennifer@cwcomm.org, ©2020 Omeros Corporation, All rights reserved. Omeros… A retrospective comparison of two control groups with similar entry criteria and baseline characteristics showed significantly higher mortality rates, at 32 percent and 53 percent, than the narsoplimab-treated group. Receive E-mail Alerts; RSS Feeds; Keyword Search. In addition, the option counterparties and/or their affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Omeros’ common stock and/or purchasing or selling Omeros’ common stock or other securities of Omeros’ in secondary market transactions following the pricing of the 2026 Convertible Notes and prior to the maturity of the 2026 Convertible Notes (and are likely to do so on each exercise date of the capped call transactions, which are expected to occur during the 50-trading day period beginning on the 51st scheduled trading day prior to the maturity date of the notes, or following any termination of any portion of the capped call transactions in connection with any repurchase, redemption or conversion of the 2026 Convertible Notes if Omeros makes the relevant election under the capped call transactions). Cataract surgery resumed beginning in the second half of May 2020, and by the end of June 2020, the run rate of weekly OMIDRIA sales approximated levels seen prior to the pandemic. This activity could increase (or reduce the size of any decrease in) the market price of Omeros’ common stock or the 2026 Convertible Notes at that time and could result in a higher effective conversion price for the 2026 Convertible Notes. Omeros makes no representation as to the accuracy of the information on sites we do not own or control and does not recommend or endorse content on any third-party websites. This compares to a net loss of $14.5 million, or $0.29 per share, in the second quarter of 2019. If the underwriters exercise their option to purchase additional 2026 Convertible Notes, Omeros expects to enter into additional capped call transactions with the option counterparties. Site Map Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with product commercialization and commercial operations, unproven preclinical and clinical development activities, the impact of COVID-19 on our business, financial condition and results of operations, regulatory oversight, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 2, 2020, as supplemented by our Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020 and subsequent filings with the SEC. Small-molecule inhibitors of GPR174 are part of Omeros’ proprietary G protein-coupled receptor (“GPCR”) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “should,” “slate,” “target,” “will,” “would” and similar expressions and variations thereof. Your use of a third-party website is at your own risk and subject to the terms and conditions of that site. Privacy Policy Investor and Media Relations Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. For the second quarter of 2020, revenues, all related to sales of OMIDRIA, were $13.5 million, down from $26.8 million for the same period in 2019 and $23.5 million for the first quarter of 2020. Omeros intends to use the net proceeds from the Equity Offering and the remainder of the net proceeds from the Notes Offering, if any, for general corporate purposes, including funding clinical trials, pre-clinical studies, manufacturing, build-out of commercial infrastructure and other costs associated with advancing its development programs and product candidates toward regulatory submissions and potential commercialization. Concurrently with the Notes Offering, Omeros expects to use a portion of the proceeds from the offering to repurchase a portion of its outstanding 2023 Convertible Notes in privately negotiated transactions. As of June 30, 2020, Omeros had $16.1 million of cash, cash equivalents and short-term investments available for operations and accounts receivable of $15.8 million. In connection with any termination of the existing capped call transaction and the related unwinding of the existing hedge position of the existing option counterparty with respect to such transaction, the existing option counterparty and/or its respective affiliates are expected to sell shares of Omeros’ common stock in secondary market transactions, and/or enter into or unwind various derivative transactions with respect to Omeros’ common stock. Omeros expects that holders of the 2023 Convertible Notes that sell their 2023 Convertible Notes to Omeros in any note repurchase transaction may enter into or unwind various derivatives with respect to Omeros’ common stock and/or purchase or sell shares of Omeros’ common stock in the market to hedge their exposure in connection with these transactions. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. The Equity Offering and the Notes Offering are being made pursuant to Omeros’ shelf registration statement on Form S-3 (File No. View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005747/en/, Jennifer Cook WilliamsCook Williams Communications, Inc.Investor and Media Relations
Inflation Definition Economics, Global Financial Meltdown Documentary Summary, Rocket Impulse, Tougher Than The Rest Lyrics, Sam's Club Credit Card Login, The Mpc Is Quizlet, Gunny Mobi Apk, Peyton Miller Tennis, Transformers Demolisher Toy, Ford Fusion Price, Was Precious Molested By Her Mother, Find Old Livejournal Account, Velvet Ant Sting Pain, Jesse Schwartz, Strive Company, Slide Hampton Roots, LEGO 10729 Juniors Cinderella’s Carriage(90)Number Of Pieces116 PiecesMinimum Age4 Years, For Life Episode 14, Timeout Meaning Computing, Tris Buffer Function, What Happened After The Great Depression, Stephanie Edwards American Idol, Is There Evidence That Better Treatment Of Mental Health Problems Reduces Other Spending, Indy Fuel Jersey Auction, Iron Brigade, Me And Mrs Jones Original Singer, Earth Png, Federal Politicians Pay Rise 2020, Prior To In A Sentence, Adopt A Pet, How Long Can An 85 Year Old Live With Dementia, Criss Angel Magic Tricks, Rocket Logo, Pandora One, Maurice Lauchner Bio, Thrilling Adventure Hour Youtube, Say What You Need To Say, Danny Miller Emmerdale, A Bucket Of Blood, Gravity Forms Get Entry Data, Ncfc U23 Tryouts, Serena Williams Wta 2020, Economy Examples, Stagflation Refers To, Jingle Bell Rock Bobby Helms, Parris Cues, Cogeco Modem,
